Original Source(s)
Related Content
FDA Issues CRL for Orviglance NDA
Ascelia Pharma plans to request a Type A meeting with the FDA following receipt of a Complete Response Letter.
July 6, 2026
-
2 min
FDA Approves Dual-Energy Catheter Ablation Platform
The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.
July 8, 2026
-
2 min
FDA Expands Gene Therapy for Younger Patients
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
July 2, 2026
-
3 min